Hydralazine - Barbeau Pharma/PDL BioPharma
Alternative Names: BPI-103Latest Information Update: 02 Oct 2021
At a glance
- Originator Barbeau Pharma
- Class Antihypertensives; Heart failure therapies; Peripheral vasodilators; Phthalazines; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypertension in pregnancy
Most Recent Events
- 10 Sep 2008 No development reported - Clinical-Phase-Unknown for Hypertension in pregnancy in USA (IV)
- 20 Mar 2007 Clinical development is ongoing for Hypertension in pregnancy
- 09 Jan 2006 ESP Pharma has been acquired and merged into PDL BioPharma